Literature DB >> 1756255

Natural history of human breast cancer: recent data and clinical implications.

M Tubiana1, S Koscielny.   

Abstract

This study of the natural history of human breast cancer was based on the analysis of a series of 3000 patients treated by radical mastectomy at a single institution (Institut Gustave Roussy) at a time when adjuvant chemotherapy was not prescribed. The follow-up of the patients ranged from 15 to 30 years; for each patient the tumor size, the number of involved axillary nodes, and the histological grade were prospectively registered. A highly significant correlation was found between tumor size and the probability of distant metastatic dissemination. The distribution of tumor sizes at metastatic spread was log-normal with a median diameter equal to 3.5 cm. The patients were subdivided into 3 groups according to the histological grade. In each subgroup there was a significant correlation between tumor size and the probability of distant spread; the distributions were log-normal and the median size was markedly larger for grade 1 tumors. Moreover the proportion of grade 1 tumors was higher in small tumors than in large ones while the reverse was observed for grade 3 tumors; these data suggest that during their growth tumors progress towards higher grades. One of the chief fundamental characteristics of a tumor seems to be its propensity for axillary node invasion. The orderly pattern of nodal involvement makes it possible to calculate the tumor size at invasion of the first axillary node in each subset of patients. A strong and highly significant correlation exists between the size of the tumor at initiation of distant metastasis and at invasion of the first lymph node. However the capacity for lymphatic spread is, on average, acquired much earlier than the capacity for metastatic spread. With a simple model based on these data it was possible to compute the proportion of patients with occult metastases as a function of tumor size, histological grade, and number of involved axillary nodes. Early invasion of axillary nodes is associated with a rapid growth rate of the primary tumor (or a high S-phase fraction). However each of these variables has an independent prognostic significance; the S-phase fraction appears as one of the strongest prognostic indicators. A model of tumor growth was used to assess the impact of screening procedures on the proportion of patients with distant metastases. The predictions of the model are consistent with the results of the screening programs.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1756255     DOI: 10.1007/bf01990028

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  44 in total

1.  Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes.

Authors:  R Arriagada; M G Lê; H Mouriesse; F Fontaine; J Dewar; F Rochard; M Spielmann; J Lacour; M Tubiana; D Sarrazin
Journal:  Radiother Oncol       Date:  1988-03       Impact factor: 6.280

2.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy.

Authors:  G Contesso; H Mouriesse; S Friedman; J Genin; D Sarrazin; J Rouesse
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

3.  [Age of metastatic adenopathies in breast cancer].

Authors:  J P Igot; Y Le Gal
Journal:  Ann Anat Pathol (Paris)       Date:  1968 Oct-Dec

4.  Therapeutic implications from a mathematical model characterizing the course of breast cancer.

Authors:  N H Slack; L E Blumenson; I D Bross
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

5.  [Growth rate and natural history of breast cancer].

Authors:  M Tubiana; P Chauvel; A Renaud; E P Malaise
Journal:  Bull Cancer       Date:  1975 Oct-Dec       Impact factor: 1.276

6.  Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study.

Authors:  J Lacour; P Bucalossi; E Cacers; G Jacobelli; T Koszarowski; M Le; C Rumeau-Rouquette; U Veronesi
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

Review 7.  Klaas Breur Medal lecture 1985. The growth and progression of human tumors: implications for management strategy.

Authors:  M Tubiana
Journal:  Radiother Oncol       Date:  1986-07       Impact factor: 6.280

8.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Authors:  R Clarke; N Brünner; B S Katzenellenbogen; E W Thompson; M J Norman; C Koppi; S Paik; M E Lippman; R B Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Tumor heterogeneity and drug resistance.

Authors:  D L Dexter; J T Leith
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

10.  Cell kinetics as a prognostic indicator in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; P Valagussa; G Di Fronzo; G Mezzanotte; G Bonadonna
Journal:  Eur J Cancer Clin Oncol       Date:  1989-08
View more
  14 in total

1.  The Canadian National Breast Screening Study: a clinician's perspective.

Authors:  A A Starreveld
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

2.  Parallel progression of tumour and metastases.

Authors:  Serge Koscielny; Maurice Tubiana
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

3.  Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

4.  A New Robust Method for Nonlinear Regression.

Authors:  M A Tabatabai; J J Kengwoung-Keumo; W M Eby; S Bae; U Manne; M Fouad; K P Singh
Journal:  J Biom Biostat       Date:  2014

5.  Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

Authors:  Marco Colleoni; Zhuoxin Sun; Karen N Price; Per Karlsson; John F Forbes; Beat Thürlimann; Lorenzo Gianni; Monica Castiglione; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

6.  A breast cancer care report card. An assessment of performance and a pursuit of value.

Authors:  J G West; M L Sutherland; J S Link; D A Margileth
Journal:  West J Med       Date:  1997-04

7.  Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants.

Authors:  Claire Saule; Solveig Menu-Hespel; Matthieu Carton; Caroline Malhaire; Pascal Cherel; Fabien Reyal; Marine Le Mentec; Eugénie Guillot; Anne Donnadieu; Nasrine Callet; Sophie Frank; Florence Coussy; Dominique Stoppa-Lyonnet; Emmanuelle Mouret-Fourme
Journal:  Eur J Hum Genet       Date:  2022-02-25       Impact factor: 5.351

8.  Measures of benefit for breast screening from the pathology database for Scotland, 1991-2001.

Authors:  T J Anderson; C Davis; F E Alexander; H M Dobson
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

9.  PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.

Authors:  M Gion; R Mione; G L Pappagallo; C Gatti; O Nascimben; M Bari; A E Leon; O Vinante; G Bruscagnin
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

10.  Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.

Authors:  Patricia Tai; Edward Yu; Vincent Vinh-Hung; Gábor Cserni; Georges Vlastos
Journal:  BMC Cancer       Date:  2004-09-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.